Drug development

Colin Kerr

Published: Monday, July 3, 2017

Novaliq GmbH has announced the successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach, in collaboration with the University of Cologne, Germany. “Based on solid results of our ongoing test series, we expect a significant impact of Novaliq’s first-in class Nov-07 programme, in comparison with existing DED drugs on an established DED mouse model,” said Philipp Steven MD, Principle Investigator, Ocular Surface Group at the Department of Ophthalmology, University of Cologne, Germany. www.novaliq.com

Latest Articles

Thinking Beyond Optics: Diversity, Equity, and Inclusion (DEI) and Unconscious Bias in Ophthalmology

Beyond Sight: A Clearer Vision for Equity in Ophthalmology

Refractions of Bias: Seeing DEI Clearly in Ophthalmology

Happy Patients, Higher Volumes

Digitalisation reduces errors and saves time, making a surgeon’s life easier.

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.